Research Article

Development and validation of an electroanalytical method for the quantification of antiviral molnupiravir and its application to the pharmaceutical sample

Volume: 29 Number: 4 July 5, 2025
EN

Development and validation of an electroanalytical method for the quantification of antiviral molnupiravir and its application to the pharmaceutical sample

Abstract

In this study, a sensitive, fast, economical, and practical voltammetric method was developed for analysing molnupiravir (MLP), an antiviral drug extensively used during the COVID-19 pandemic, without the need for modifying the glassy carbon (GC) electrode surface. During the electroanalysis, an oxidation peak for MLP was detected at 0.72555 V on the GC electrode. The method exhibited linearity across a concentration range of 1 - 250 µM for MLP with 0.33 µM of detection limit. Furthermore, with a 99.81% recovery from its pharmaceutical form, the method's effectiveness was validated. These results strongly indicate that this method is suitable for routine quality control of molnupiravir and may serve as a model for analysing other antiviral drugs.

Keywords

References

  1. [1] Qu J-M, Cao B, Chen R-C. Respiratory virus and COVID-19. In: Qu J-M, Cao B, Chen R-C (Eds). COVID-19 The Essentials of Prevention and Treatment. Elsevier, USA, 2021, pp. 1-6. [2] Kotra LP. Viral Disease. In: Enna SJ, Bylund DB (Eds). xPharm: The Comprehensive Pharmacology Reference. Elsevier, New York, 2007, pp. 1-3.
  2. [3] Dunn EF, Connor JH. HijAkt: The PI3K/Akt Pathway in Virus Replication and Pathogenesis. In: Shenolikar S.(Ed.) Progress in Molecular Biology and Translational Science. Academic Press, USA, 2012, pp. 223-250. [4] Chappell JD, Dermody TS. Biology of Viruses and Viral Diseases. In: Bennett JE, Dolin R, Blaser MJ (Eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier/Saunders, Philadelphia, 2015, pp. 1681-1693.e1684.
  3. [5] Meganck RM, Baric RS. Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat Med. 2021; 27(3): 401-410. https://doi.org/10.1038/s41591-021-01282-0.
  4. [6] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3.
  5. [7] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383(27): 2603-2615. https://doi.org/10.1056/NEJMoa2034577.
  6. [8] Brown AN, Lang Y, Zhou J, Franco EJ, Hanrahan KC, Bulitta JB, Drusano GL. Why molnupiravir fails in hospitalized patients. Mbio 2022; 13(6): e02916-02922. https://doi.org/10.1128/mbio.02916-22.
  7. [9] WHO, World Health Organisation. https://data.who.int/dashboards/covid19/deaths?n=c (accessed 22 August 2024)
  8. [10] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384(5): 403-416. https://doi.org/10.1056/nejmoa2035389.

Details

Primary Language

English

Subjects

Pharmaceutical Analytical Chemistry

Journal Section

Research Article

Authors

Publication Date

July 5, 2025

Submission Date

August 26, 2024

Acceptance Date

September 27, 2024

Published in Issue

Year 2025 Volume: 29 Number: 4

APA
Ateş, A. K. (2025). Development and validation of an electroanalytical method for the quantification of antiviral molnupiravir and its application to the pharmaceutical sample. Journal of Research in Pharmacy, 29(4), 1746-1752. https://doi.org/10.12991/jrespharm.1734697
AMA
1.Ateş AK. Development and validation of an electroanalytical method for the quantification of antiviral molnupiravir and its application to the pharmaceutical sample. J. Res. Pharm. 2025;29(4):1746-1752. doi:10.12991/jrespharm.1734697
Chicago
Ateş, Ali Kemal. 2025. “Development and Validation of an Electroanalytical Method for the Quantification of Antiviral Molnupiravir and Its Application to the Pharmaceutical Sample”. Journal of Research in Pharmacy 29 (4): 1746-52. https://doi.org/10.12991/jrespharm.1734697.
EndNote
Ateş AK (July 1, 2025) Development and validation of an electroanalytical method for the quantification of antiviral molnupiravir and its application to the pharmaceutical sample. Journal of Research in Pharmacy 29 4 1746–1752.
IEEE
[1]A. K. Ateş, “Development and validation of an electroanalytical method for the quantification of antiviral molnupiravir and its application to the pharmaceutical sample”, J. Res. Pharm., vol. 29, no. 4, pp. 1746–1752, July 2025, doi: 10.12991/jrespharm.1734697.
ISNAD
Ateş, Ali Kemal. “Development and Validation of an Electroanalytical Method for the Quantification of Antiviral Molnupiravir and Its Application to the Pharmaceutical Sample”. Journal of Research in Pharmacy 29/4 (July 1, 2025): 1746-1752. https://doi.org/10.12991/jrespharm.1734697.
JAMA
1.Ateş AK. Development and validation of an electroanalytical method for the quantification of antiviral molnupiravir and its application to the pharmaceutical sample. J. Res. Pharm. 2025;29:1746–1752.
MLA
Ateş, Ali Kemal. “Development and Validation of an Electroanalytical Method for the Quantification of Antiviral Molnupiravir and Its Application to the Pharmaceutical Sample”. Journal of Research in Pharmacy, vol. 29, no. 4, July 2025, pp. 1746-52, doi:10.12991/jrespharm.1734697.
Vancouver
1.Ali Kemal Ateş. Development and validation of an electroanalytical method for the quantification of antiviral molnupiravir and its application to the pharmaceutical sample. J. Res. Pharm. 2025 Jul. 1;29(4):1746-52. doi:10.12991/jrespharm.1734697